ESMO 2022
Feb 24, 2023
Top 10 Expected Oncology Drug Launches in 2023
Cancer is the world’s second leading cause of death. Every year, 10 million people die from cancer. Cancer kills 70% of people in low-to-middle-income countries. Cancer is estimated to cost the global economy USD 1.16 trillion per year. Millions of lives could be saved annually by implementing resource-appropriate ...
Read More...
Nov 25, 2022
ESMO Asia 2022: Role of EGFR and ALK mutations in the East Asian Lung Cancer Market
Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...
Read More...
Sep 13, 2022
Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial
Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
